Synergy Research Group debuts Ukraine Orange Paper

17 September 2014

Synergy Research Group has debuted the Ukraine Orange Paper. The comprehensive report gives the best detail and analysis of the state of clinical trials in Ukraine.

Data was pulled from a variety of sources, including the Ministry of Health in Ukraine and the Food and Drug Administration, etc. The Ukraine Orange Paper will give readers actionable intelligence on clinical trials in the country.

The original Synergy Orange Paper is relied on by the local and international life science and business community involved in clinical trials in Russia since 2007. The Ukraine version will allow readers to compare current data with previous numbers to see year-over-year changes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >